New products to contribute meaningful revenue in 2024

M N 21 Mar 2024 CMB International Global Markets | Equity Research | Company Update CSPC Pharmaceutical (1093 HK) New products to contribute meaningful revenue in 2024  FY23 results in line with expectation. CSPC reported FY23 revenue of Target Price HK$7.76 RMB31.45bn (+1.7% YoY) and attributable net profit of RMB5.87bn (-3.6% (Previous TP HK$8.16) YoY), in line with our previous estimates. The adjusted attributable net profit Up/Downside 21.1% (excl. impact from financial assets, share-based compensation ...